

Notice: June 19, 2026

To: Senior Care Options and One Care Providers

From: Commonwealth Care Alliance® (CCA)

Subject: Important Update: Coverage Changes for GLP-1 and Anti-Obesity Medications

Effective Date: July 1, 2026

Summary

Effective July 1, 2026, Commonwealth Care Alliance® (CCA) will update coverage for certain medications prescribed for obesity or overweight for members enrolled in SCO and One Care, in alignment with anticipated changes to [MassHealth regulations](#).

What this means for your patients

- Some medications commonly prescribed for obesity or weight management will no longer be covered for SCO and One Care members.
- Coverage will continue for certain medically accepted uses, with updated prior authorization (PA) requirements.
- [CMS GLP-1 Bridge](#) Information is available for providers seeking additional federal guidance.

What's Changing

The following medications will no longer be covered when prescribed for **obesity** or **weight management** for SCO and One Care members:

- GLP-1 and related weight-loss medications, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
- Other anti-obesity medications, including, Xenical (orlistat), phentermine products such as Lomaira and Adipex-P, benzphetamine, diethylpropion, and phendimetrazine

Prior Authorization (PA) Updates

New prior authorizations needed for approved indications. Coverage of glucagon-like peptide-1 (GLP-1) or GIP (glucose-dependent insulintropic polypeptide)/GLP-1 medications may continue after July 1, 2026, for members previously approved for the medically accepted indications listed below. A new prior authorization request is required.

- **Established cardiovascular disease** to reduce the risk of **major adverse cardiovascular events (MACE)**
- **Metabolic dysfunction-associated steatohepatitis (MASH)**
- **Moderate to severe obstructive sleep apnea (OSA)**

Existing Prior Authorizations: Review and Resubmission Requirements

Providers should review existing prior authorizations for the anti-obesity agents listed above, as some authorizations will end on June 30, 2026, and require resubmission.

What Providers Need to Do

- **Review affected members** currently prescribed these medications.
- **Submit new prior authorization (PA) requests** for members who meet approved indications.
- **Consider alternative treatment options** for members who do not meet coverage criteria.
- **Inform office and clinical staff** so they can address member inquiries.

Questions?

For questions, contact CCA Provider Services at **1-866-420-9332**. Hours are 8:00 a.m. to 5:00 p.m. Monday through Wednesday and Friday, and 8:30 a.m. to 5:00 p.m. Thursday, Eastern Time.

Commonwealth Care Alliance | 2 Avenue de Lafayette, 5th floor | Boston, MA 02111 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email & social marketing for free!